News Novartis nabs cardio drug with $1.4bn Tourmaline buy Novartis has bulked up in cardiology with a $1.4bn takeover of Tourmaline Bio and its drug for atherosclerotic cardiovascular disease (ASCVD).
News Aspen, Bambusa close IPOs as Corxel takes SPAC route Aspen Neuroscience and Bambusa Therapeutics get their Nasdaq IPOs over the line, while Corxel eyes a debut via a blank-cheque company merger.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.